Oral Ozempic Arrives as Q1 Results Loom
Novo Nordisk launches oral Ozempic in US pharmacies, faces Q1 earnings test amid margin concerns, and prepares obesity…
Novo Nordisk’s Ozempic Pill Hits Shelves as Q1 Earnings Loom and Valuation Debate Deepens
Novo Nordisk faces a pivotal week with Ozempic oral launch, expected Q1 earnings decline, and a 36% stock…
Q1 Earnings Loom as Valuation Debate Intensifies
Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and…
Canadian Generic Launch and Q1 Results Loom
Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…